Aberdeen Group plc Buys 20,097 Shares of STERIS plc $STE

Aberdeen Group plc raised its stake in shares of STERIS plc (NYSE:STE) by 25.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,088 shares of the medical equipment provider’s stock after purchasing an additional 20,097 shares during the period. Aberdeen Group plc owned 0.10% of STERIS worth $25,374,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Trust Co. of Vermont increased its position in STERIS by 30.2% in the 4th quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 38 shares during the period. Magnolia Capital Advisors LLC grew its position in STERIS by 1.2% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock worth $888,000 after purchasing an additional 41 shares during the last quarter. Colonial Trust Co SC increased its holdings in shares of STERIS by 0.3% during the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock worth $3,051,000 after purchasing an additional 42 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 45 shares during the period. Finally, Fifth Third Bancorp raised its position in shares of STERIS by 1.6% during the third quarter. Fifth Third Bancorp now owns 2,953 shares of the medical equipment provider’s stock valued at $731,000 after buying an additional 46 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Trading Down 0.1%

Shares of STE opened at $218.42 on Monday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock has a market cap of $21.42 billion, a PE ratio of 30.46 and a beta of 1.07. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The stock has a 50 day simple moving average of $238.53 and a 200-day simple moving average of $247.74.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s revenue was up 9.2% compared to the same quarter last year. During the same period last year, the business posted $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, sell-side analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 19th. Investors of record on Tuesday, February 17th were given a dividend of $0.63 per share. The ex-dividend date was Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS’s dividend payout ratio is 35.15%.

Insider Buying and Selling

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director owned 705 shares in the company, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.07% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STE. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.